We provide evidence that pharmacological inhibition of METTL3 could be a novel therapeutic approach for high-risk NB, by inducing differentiation and increasing the efficacy of the chemotherapeutic drugs (Fig. 7). The gene discussed is METTL3; the disease is neuroblastoma.